The challenges posed by cancer heterogeneity - PubMed

Affiliations

• PMID: 22781679
• DOI: 10.1038/nbt.2294

The challenges posed by cancer heterogeneity

Sangeeta Bhatia et al. Nat Biotechnol. 2012.

Similar articles

• Addressing intra-tumoral heterogeneity and therapy resistance.

  Rybinski B, Yun K. Rybinski B, et al. Oncotarget. 2016 Nov 1;7(44):72322-72342. doi: 10.18632/oncotarget.11875. Oncotarget. 2016. PMID: 27608848 Free PMC article. Review.

• Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.

  Nijman SMB. Nijman SMB. Trends Cancer. 2020 Jun;6(6):454-461. doi: 10.1016/j.trecan.2020.02.016. Epub 2020 Mar 13. Trends Cancer. 2020. PMID: 32460001 Review.

• Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

  Easwaran H, Tsai HC, Baylin SB. Easwaran H, et al. Mol Cell. 2014 Jun 5;54(5):716-27. doi: 10.1016/j.molcel.2014.05.015. Mol Cell. 2014. PMID: 24905005 Free PMC article. Review.

• Drug resistance, epigenetics, and tumor cell heterogeneity.

  Hoey T. Hoey T. Sci Transl Med. 2010 Apr 21;2(28):28ps19. doi: 10.1126/scitranslmed.3001056. Sci Transl Med. 2010. PMID: 20410528

• Intra-tumor heterogeneity from a cancer stem cell perspective.

  Prasetyanti PR, Medema JP. Prasetyanti PR, et al. Mol Cancer. 2017 Feb 16;16(1):41. doi: 10.1186/s12943-017-0600-4. Mol Cancer. 2017. PMID: 28209166 Free PMC article. Review.

Cited by

• Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging.

  Miwa S, Yano S, Kimura H, Yamamoto M, Toneri M, Matsumoto Y, Uehara F, Hiroshima Y, Murakami T, Hayashi K, Yamamoto N, Bouvet M, Fujiwara T, Tsuchiya H, Hoffman RM. Miwa S, et al. Cell Cycle. 2015;14(4):621-9. doi: 10.4161/15384101.2014.991604. Cell Cycle. 2015. PMID: 25551170 Free PMC article.

• Image-guided cancer surgery using near-infrared fluorescence.

  Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Vahrmeijer AL, et al. Nat Rev Clin Oncol. 2013 Sep;10(9):507-18. doi: 10.1038/nrclinonc.2013.123. Epub 2013 Jul 23. Nat Rev Clin Oncol. 2013. PMID: 23881033 Free PMC article. Review.

• Cancer heterogeneity is not compatible with one unique cancer cell metabolic map.

  Strickaert A, Saiselet M, Dom G, De Deken X, Dumont JE, Feron O, Sonveaux P, Maenhaut C. Strickaert A, et al. Oncogene. 2017 May 11;36(19):2637-2642. doi: 10.1038/onc.2016.411. Epub 2016 Oct 31. Oncogene. 2017. PMID: 27797377 Free PMC article. Review.

• A Model-System to Address the Impact of Phenotypic Heterogeneity and Plasticity on the Development of Cancer Therapies.

  Jong ED, Chan ICW, Nedelcu AM. Jong ED, et al. Front Oncol. 2019 Aug 29;9:842. doi: 10.3389/fonc.2019.00842. eCollection 2019. Front Oncol. 2019. PMID: 31555595 Free PMC article.

• Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.

  Zhu J, Huang H, Dong S, Ge L, Zhang Y. Zhu J, et al. Theranostics. 2014 Jul 13;4(9):931-44. doi: 10.7150/thno.9663. eCollection 2014. Theranostics. 2014. PMID: 25057317 Free PMC article. Review.

References

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database